Showing results (1-10 of 505) with videos related to
Sort By:
Pageof 51
Journal of Crohn'S & Colitis|August 28, 2025
Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics studyZhigang Wang, Marc Ferrante, Séverine Vermeire, et al.British Journal of Clinical Pharmacology|July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's diseaseZhigang Wang, Bram Verstockt, João Sabino, et al.Pharmaceutics|October 23, 2021
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative ColitisRuben Faelens, Zhigang Wang, Thomas Bouillon, et al.British Journal of Clinical Pharmacology|May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's diseaseErwin Dreesen, Sophie Berends, David Laharie, et al.Inflammatory Bowel Diseases|March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical SamplesAnn Gils, Thomas Van Stappen, Erwin Dreesen, et al.British Journal of Clinical Pharmacology|January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitisErwin Dreesen, Ruben Faelens, Gert Van Assche, et al.Clinical Pharmacokinetics|April 8, 2026
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's DiseaseWei Zhang, Zhigang Wang, Thierry Dervieux, et al.Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.Journal of Pediatric Gastroenterology and Nutrition|January 12, 2019
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.Therapeutic Drug Monitoring|January 12, 2019
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.Pageof 51